Figure 1. Strategy used for integrated ⁶⁴Cu therapy.

(A) Schematic representation of the integrated ⁶⁴Cu-therapy approach used for treating early- and late-phase peritoneal dissemination. (B) Small lesions in the early-phase peritoneal-dissemination mouse model with HCT116-RFP cells, detected with a stereoscopic fluorescence microscope. This model involved small tumors with diameters of approximately 2 mm or less. (C) Accumulation of ip- or iv-injected ⁶⁴Cu-PCTA-cetuximab over time in small tumors in the early-phase peritoneal-dissemination mouse model with HCT116-RFP cells. Values are shown as the mean ± SD; n = 4 for each time point. ^*P < 0.05 between the ip- and iv-injection results (2-way ANOVA).